Kornimate/medical-research-clean huggingface dataset:
participatory research for suicide prevention in autism

Conditions: Autism; Suicide Prevention

Summary: the goal of this study is to pilot test a new educational intervention for organization members focused on suicide prevention for autistic people. the main questions it aims to answer are: * does participating in the intervention increase participants' knowledge, skills, and actions to support suicide prevention for autistic people? * what feedback do participants have to help improve the intervention? participants will: * engage in a four-part virtual educational intervention * answer questions via online survey before, after, and 3-months after the intervention * participate in an optional interview to provide feedback

this study will pilot test a new four-part virtual educational intervention called forming love around autistic people to prevent suicide (flaps). participants will be active members of an organization (e.g., paid employee, volunteer, stakeholder) whose work impacts autistic people. they will participate in four virtual educational sessions led by trained facilitators. the educational intervention will provide current research evidence and community-informed information about suicide risk and prevention, and engage participants in active discussions to expand their knowledge and skills as well as to promote action planning to support suicide prevention for autistic people in their community. participants will provide demographic and descriptive information and complete the steps toward prevention (autism community suicide prevention) measure at three time-points (pre-intervention, post-intervention \[approximately 2 months after baseline\], and 3-months after intervention). the steps toward prevention (autism community suicide prevention) measure will assess participants' knowledge, skills, and actions to support suicide prevention for autistic people. they will also be provided an option to complete a short interview to provide feedback about the flaps intervention.

Eligibility criteria:
inclusion criteria: * active member of an organization whose work impacts autistic people * age 18+ * fluent english language to participate in virtual educational intervention exclusion criteria: * no access to an internet-connected device * unable to participate in a virtual educational intervention

Keywords: educational intervention pilot test
combined effects of whole body vibration and abdominal binders on outcome measures of constipation in postnatal women

Conditions: Constipation in Postnatal Women; Constipation

Summary: constipation is a prevalent issue among postnatal women, often resulting in significant discomfort and reduced quality of life. traditional treatments like dietary adjustments and laxatives frequently provide only temporary relief and may lead to dependency. whole-body vibration therapy and abdominal binders have emerged as promising non-invasive interventions for improving bowel function and relieving constipation.

constipation is a complex condition arising due to many interrelated causes. dietary inadequacies, most notably for fiber or fluid, often constitute a centerpiece of constipation. but other lifestyle factors including lack of movement and irregular bowel movements are also to blame. known conditions affecting the gut motility, from medical perspective, include irritable bowel syndrome (ibs), diabetes, hypothyroidism, and neurological disorders including parkinson's disease. often listed as a side effect in medications such as opiates, antacids and antidepressants for example. additionally, gut brain axis demonstrates that psychological aspects play a substantial part in the well being of the gut, since stress and anxiety frequently make matters worse. it is important to understand the causes of constipation to develop treatments.it is usually described as occurring less than three times per week, difficult to pass stools or passage of stools that does not feel satisfactory. whereas, acute constipation can be often attributed to alteration in diet and water intake or stress, the chronic constipation is a long-standing pathological entity which can negatively affect the quality of life. whole body vibration therapy (wbv) is a therapeutic modality that utilizes mechanical vibrations to excite muscle, nerve and tissue structures in the body. wbv is typically administered on a vibrating platform where the device is either controlled to deliver vibrations at specified frequencies and amplitudes as the individual performs a standing, sitting, or lying position. the vibrations produce rapid, involuntary muscle contractions- and result in a similar exercising effect without the impact to your body. abdominal binders are conventionally used for physical support but recent evidence supports their use in improving bowel function as increased abdominal muscle recruitment and intra-abdominal pressure, both integral to a healthy peristaltic push.

Eligibility criteria:
inclusion criteria: * females age 22-35 years * females underwent c-section were included in the study * participants who had severe constipation * primary gravida * women who had 6 months of postpartum period * single fetus pregnancy exclusion criteria: * females who had normal delivery were excluded * history of episiotomy * participants taking laxative were excluded * history of post cesarean abdominal suture infections

Keywords: constipation, c-section, pelvic floor, hemorrhoids, postpartum
an observational study of hemoglobin stability in chronic kidney disease patients on dialysis treated with mircera (methoxy polyethylene glycol-epoetin beta)

Conditions: Anemia

Summary: this prospective, multicenter, observational study will evaluate the impact of comorbidities on hemoglobin stability in chronic kidney disease patients on dialysis treated with mircera (methoxy polyethylene glycol-epoetin beta). eligible patients will be followed for 6 months of treatment.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * chronic kidney disease patients on hemodialysis or hemodiafiltration for at least 3 months * previously treated with an erythropoietin stimulating agent (esa) * patient for whom the investigator decided to initiate treatment with mircera for medical reasons * last hemoglobin level before initiation of mircera within the range of 10-12 g/dl exclusion criteria: * current participation in a clinical trial on renal anemia
neoadjuvant chemoradiation with nal-iri and capecitabine guided by ugt1a1 status in patients with rectal cancer

Conditions: Rectal Cancer

Summary: this single-arm trial will explore the efficacy and safety of long-course neoadjuvant chemoradiation with liposomal irinotecan and capecitabine guided by ugt1a1 status in patients with locally advanced rectal cancer.

this is a single-center, single-arm, prospective clinical study. the aim of this study is to explore the short-term and long-term efficacy and safety of total neoadjuvant therapy with irinotecan liposome in patients with locally advanced rectal cancer. patients' nutritional status, quality of life, changes in symptoms, and adverse events will also be regularly assessed and registered during the implementation phase of the study, and patients will be treated promptly if symptoms are assessed as positive.

Eligibility criteria:
inclusion criteria: * age: 18\~75 years old. * eastern cooperative oncology group (ecog) performance status of 0\~1. * histopathologically confirmed rectal adenocarcinoma. * the lower edge of the primary tumor is located below the peritoneal reflection or located ≤ 10 cm above the anal verge. * clinical stage: t3-4nanym0 or t1-2n+m0. * adequate bone marrow function as evidenced by: absolute neutrophil count (anc) ≥1.5×10\^9/l, platelet count ≥100×10\^9/l, hemoglobin (hb) ≥90 g/l. * adequate hepatic function as evidenced by: total bilirubin ≤1.5 × upper limit of normal (uln), aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤2.5×uln, serum albumin ≥3 g/dl. * adequate renal function as evidenced by: serum creatinine (cr) ≤1.5 × uln or creatinine clearance ≥60 ml/min. * be willing to undergo ugt1a1 gene testing and ugt1a1 genotype of \*1\*1 or \*1\*28. * accept the neoadjuvant chemoradiotherapy protocol of this study and sign the informed consent. exclusion criteria: * any other malignancy within 5 years, with the exception of cured in-situ carcinoma or basal cell carcinoma etc. * active, uncontrolled bacterial, viral, or fungal infections that require systemic treatment. * active hiv infection. * combined with uncontrollable systemic diseases. * history of allergy or hypersensitivity to drug or any of their excipients. * any clinical indicators indicating contraindications to radiotherapy/chemotherapy and surgery. * use of strong inhibitors or inducers of cyp3a, cyp2c8 and ugt1a1. * pregnant or breastfeeding women, or subjects of childbearing age who refuse contraception. * patients with poor cognitive abilities who are unable to answer questions, fill out questionnaires, or have mental disorders. * patients who do not meet the inclusion criteria; patients who meet the inclusion criteria but are not suitable to participate in this trial judged by the investigator.

Keywords: ugt1a1 liposomal irinotecan total neoadjuvant therapy
influence of nociception level monitor (nol) guided analgesic delivery on robot-assisted colorectal surgery

Conditions: Opioid Use, Unspecified; Pain, Postoperative

Summary: being relatively new, the nol monitor may offer interesting observations in perioperative nociception levels and appropriate analgesic consumption in diverse surgeries, including robot-assisted surgery. these observations may supplement the current efforts towards further advantages in rapid restitution. therefore, the investigators planned a trial where intra-operative analgesics were guided using an nol monitor to study if intra-operative nol guidance influences peri-operative analgesic consumption, postoperative length of stay and quality of recovery of patients subjected for robot-assisted surgery.

during anesthesia for surgical procedures, anesthetic and muscle relaxant drugs can be meticulously administered using bispectral index (bis) and neuromuscular monitors. however, analgesic drugs are still dispensed using poor surrogate parameters such as heart rate and blood pressure. this subjective dosing of analgesic drugs may invariably lead to inappropriate intra-operative consumption. this may result in tachycardia, hypertension, and postoperative pain due to e.g. insufficient analgesia, or hypotension, bradycardia, respiratory depression and post-operative nausea and vomiting (ponv) secondary to excessive analgesia. these effects may be detrimental to the patients especially those with multiple comorbidities with limited vital organ reserves such as patients classified to iii or iv by the american society of anaesthesia classification (asa) similarly, immediate postoperative recovery may also get delayed due to pain, unstable hemodynamics, nausea and vomiting. in that context, there has long been search for a monitor which can guide meticulous administration of analgesics. recently, a nociception level monitor (nol) based on advanced software algorithms using multiple physiological parameters has been developed. it offers an objective score (nol index) which relates to the level of intra-operative pain. nol technology has been validated and found superior to existing pain indicators in peer-reviewed publications. the nol monitor may offer interesting observations in perioperative nociception levels and appropriate analgesic consumption in diverse surgeries, including robot-assisted surgery. these observations may supplement the current efforts towards further advantages in rapid restitution. therefore, the investigators are planning a trial where intra-operative analgesics are guided using an nol monitor.

Eligibility criteria:
inclusion criteria: * american society of anaesthesiologists score iii-iv * scheduled for elective major robot-assisted colorectal surgeries exclusion criteria: * inability to give informed consent * planned spinal or epidural anaesthesia * all forms of regional anaesthesia, including wound infiltration * nonelective procedures * pregnancy or lactation * atrial fibrillation

Keywords: nociception, robotic surgery, opioids, postoperative recovery
evaluation of wound dressings in the reduction of shear- force

Conditions: Pressure Ulcer

Summary: the purpose of this study is to investigate if wound dressings are capable in reducing the effects of shear- force at the skin. with our own shear- force model we are able to apply 19 newton shear- force combined with 9 newton pressure at the skin of the non- dominant forearm. after half an hour we measure il-1alpha/ total protein- ratio, cutaneous blood flow (laser doppler, moor ldi) and the erythema index (dsmiicolormeter) which occurs as an effect of shear- force application at the skin. then, we apply 19 newton shear- force combined with 9 newton pressure at the dominant fore-arm but this time we put a wound dressing between the skin and shear- force model. after half an hour we measure the il-1alpha/total protein-ratio, cutaneous blood flow and the erythema index. this research consists of three research day, each day we are going to investigate a different wound dressing


Eligibility criteria:
inclusion criteria: * healhty volunteer * age 18- 30 * bmi 20- 30 exclusion criteria: * trauma fore-arms * diabetes mellitus type i or type ii * the use of nsaid's in the last 7 days * vascular diseases * muscular dystrophy * malignancy * participant is unable to give informed consent
lentils as a functional food to improve glucose and decrease cardiovascular risk

Conditions: Obesity; Hypercholesterolemia

Summary: compared to control foods, consumption of 3 cups of cooked lentils given weekly for 12 weeks will significantly improve glucose tolerance and lower ldl-cholesterol in individuals with high cholesterol and obesity.

this is a multi-site, randomized, controlled, parallel group food study designed to examine the health benefits, specifically glucose tolerance, insulin sensitivity and ldl-cholesterol in overweight individuals with a high waist circumference and elevated ldl-cholesterol. recruitment will consist of approximately 102 overweight participants (n= 51 participants per site, at 2 sites located in winnipeg and toronto) with high waist circumference and elevated ldl-cholesterol.

Eligibility criteria:
inclusion criteria: * male or non-pregnant, non-lactating females aged 30 to 75 years; * body mass index of ≤40 kg/m2 and ≥23 kg/m2 if asian or ≥25 kg/m2 if non-asian; * waist circumference ≥94 cm for males and ≥80 cm for females of asian ethnicity,and ≥102 cm for males and ≥88 cm of non-asian ethnicity; * fasting plasma glucose \<7 mmol/l; * fasting triglycerides \ 2.50 mmol/l and \<5.00 mmol/l; * must be on a stable regime for the past 3 months if taking medications to treat hypertension or if taking vitamin and mineral/dietary/herbal supplements; * stable body weight (±3 kg) for the past 3 months exclusion criteria: * previous diagnosis of type 2 diabetes; * high pulse consumption (≥2 servings per week); * presence of liver disease (aspartate transaminase \>2 times upper normal limit), renal insufficiency (creatinine \>1.5 times upper normal limit); inflammatory bowel disease or other gastrointestinal disorders influencing gastrointestinal motility or nutrient absorption; * use of medication which influence carbohydrate metabolism (i.e., steroids), or medications used to treat diabetes or to lower blood lipids, or any active medical or surgical conditions within the past 3 months; * conditions or medications which are likely to increase the risk to the participants or study personnel, or to reduce the ability of the participant to comply with the protocol, or affect the results; * history of gastrointestinal reactions or allergies to lentils or potato-based foods, or to one or more ingredients in the study foods which significantly limits the number of study foods that can be consumed.

Keywords: overweight obese obesity cholesterol hypercholesterolemia ldl-cholesterol
sickle cell disease biofluid chip technology (scd biochip)

Conditions: Sickle Cell Disease

Summary: 'sickle-shaped' anemia was first clinically described in the us in 1910, and the mutated heritable sickle hemoglobin molecule was identified in 1949. the pathophysiology of scd is a consequence of abnormal polymerization of sickle hemoglobin (hbs) and its effects on red cell membrane properties, shape, and density, and subsequent critical changes in inflammatory cell and endothelial cell function. our goal is to understand the impact of cma abnormalities in scd, by interrogating a number of recognized interactions in a range of clinical phenotypes. to date, correlative studies in scd, by us and others, have range between clinical reports, based on tests, interventions, and chart review of individuals or groups of individuals and, at the other extreme, identification of functional gene polymorphisms based on population studies. the investigators wish to augment these studies through a systematic examination of cellular membrane properties and activation status. of hematologic disorders, scd may be unusually susceptible to such an examination.

novel biofluidic chip technology can investigate surface characteristics that are typically measured with conventional techniques, such as fluorescent activated cell sorting (facs), immunohistochemistry, or microscopic imaging methods. in facs, cells of interest are isolated, extensively processed, incubated with a fluorescent-labeled antibody and sorted by optical recognition. in the proposed scd biofluidic chip (scd biochip), the interrogating antibody coats the microchannel surface and captures the cell population(s) of interest, without processing, incubation, or in vitro manipulation. the scd biochip can also quantitate cellular adherence to experimental biological surfaces that are comprised of subcellular components. the scd biochip is technically simple and experimentally flexible, whereby the population of interest is retained on the chip and quantitated in situ. the microchip system allows retrieval of viable isolated cells for potential downstream processing, analysis, and in vitro culture.

Eligibility criteria:
inclusion criteria * male or female ≥12 years of age at the time of consent (enrollment). * documentation sickle cell disease, including hbss or compound heterozygus hbsc- or hbsβ- thalassemia diagnosis as evidenced by one or more clinical features. * written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. exclusion criteria * presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.

Keywords: sickle cell disease biofluidic chip technology
switch and maintenance study of intravenous injections of r744 to hemodialysis patients (phase ⅲ study)

Conditions: Hemodialysis Patients

Summary: this study will assess the efficacy and safety of intravenous r744 in renal anemia patients on hemodialysis.


Eligibility criteria:
inclusion criteria: * patients who have been receiving hemodialysis 3 times a week for at least 12 weeks before registration * patients aged ≥ 20 years at the time of obtaining consent patients who have been receiving a rhuepo preparation at least once a week for at least 8 weeks before registration * patients whose mean value of hb concentrations determined before the first dialysis of each week within 8 weeks prior to the registration has been between ≥ 10.0 g/dl and \<12.0 g/dl * patients whose transferrin saturation has been ≥ 20 % or ferritin has been * 100ng/ml at any one time point within 8 weeks before registration exclusion criteria: * patients with hardly controllable hypertension (patients whose diastolic blood pressure has been ≥ 100 mmhg on more than 1/3 of the determining occasions within 12 weeks before registration) * patients with congestive cardiac failure (≥ class iii in nyha cardiac function classification) * female patients who are pregnant, lactating, possibly pregnant or not willing to take a contraceptive measure in the period from the day of starting the treatment with the study drug to 90 days after the day of the last dose of the study drug * patients with complication of myocardial infarction, pulmonary infarction or cerebral infarction (excluding asymptomatic cerebral infarction) * patients confirmed to have serious allergy or serious drug allergy (shock, anaphylactoid symptom) * patients hypersensitive to a rhuepo preparation * patients with malignant tumor (including hemic malignant tumor), severe infection, systemic hemic disease (osteomyelodysplasia syndrome, hemoglobinopathy, etc.), hemolytic anemia or apparent hemorrhagic lesion such as digestive tract hemorrhage * patients who have received an anabolic hormone preparation, testosterone enanthate or mepitiostane within 12 weeks before registration * patients who have received another investigational drug within 12 weeks before registration * patients who have received r744 before registration * patients whose ast(got) value ≥ 100 iu/l or alt(gpt) value ≥ 100 iu/l before registration * patients who have received erythrocyte transfusion within the last 16 weeks before registration * patients for whom a surgical operation involved with heavy bleeding is planned during the study period * in addition, patients who are judged as ineligible to participate in this study by the investigator or sub-investigator
real-world study of dlbcl with different genetic subtypes

Conditions: DLBCL - Diffuse Large B Cell Lymphoma; Lymphoma

Summary: to collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of dlbcl patients with different genetic suptypes

dlbcl is a highly common malignant tumor in asia. the aim of the study is to observe and explore the clinical information on dlbcl patients with different genetic subtypes and to analyze the clinical characteristics and prognosis of different molecular subtypes of dlbcl. this study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. the medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors. the results can guide future precision therapy for dlbcl.

Eligibility criteria:
inclusion criteria: * histologically-confirmed diffuse large b-cell lymphoma (dlbcl) * genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: mcd, bn2, n1, st2, a53, ezb (myc+, myc-) and others * fully comprehension and signature of the informed consent form (icf) for participation exclusion criteria: * those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period * severe mental illness * patients deemed unsuitable for inclusion by the investigator

Keywords: lymphoma dlbcl genetic subtype real world analysis